The Japanese Journal of Dermatology
Online ISSN : 1346-8146
Print ISSN : 0021-499X
ISSN-L : 0021-499X
Volume 132, Issue 6
Displaying 1-9 of 9 articles from this issue
Obituary
Guidance
Seminar for Medical Education
Original Articles
  • Yu Sasaki, Takumi Sugiyama, Yoshimitsu Takamatsu, Takumi Tajima, Gen T ...
    2022 Volume 132 Issue 6 Pages 1463-1470
    Published: May 20, 2022
    Released on J-STAGE: May 20, 2022
    JOURNAL RESTRICTED ACCESS

    To examine actual medical treatment data on acne conglobata in Japan, we surveyed the number of patients, backgrounds, type of medical institutions, clinical departments, and prescribed medications using health insurance claims data. Of the 8,521,265 patients analyzed, 2,726 were diagnosed with acne conglobata; therefore, the number of patients with this type of acne in Japan was estimated to be 29,171, and the prevalence was estimated to be 32.0 per 100,000 in the population. Oral antibiotics were prescribed to 72.3% of the patients; 10.3% of them were prescribed them for 91 days or more per year. Additionally, 70.4% of patients were prescribed topical antibacterials; 6.3% were prescribed more than 101 g per year. Notably, 19.5% of patients visited a surgical department. Our study suggests that patients with acne conglobata are difficult to treat; they receive long-term antibacterial drugs and undergo surgical procedures.

    Download PDF (843K)
Case Reports
  • Michiko Hasegawa, Ryuichi Saito, Atsushi Tamura
    2022 Volume 132 Issue 6 Pages 1471-1478
    Published: May 20, 2022
    Released on J-STAGE: May 20, 2022
    JOURNAL RESTRICTED ACCESS

    Angiomyofibroblastoma is a rare, benign, slowly growing, mesenchymal tumor that occurs mainly in the female vulva. It can be easily misdiagnosed as aggressive angiomyxoma; both tumors share some clinicopathological features, including a preferential location on the vulva and hypocellular pathology. We report a 53-year-old woman with a vulvar mass of 3 years' duration that had rapidly enlarged over the previous year. Physical examinations revealed a 10×8×8-cm pedunculated flesh-colored tumor on the right labium majus. The surgically excised tumor was well-circumscribed without invasion of the surrounding tissue. Histopathologically, the tumor showed alternating hypercellular and hypocellular areas accompanied by vascular hyperplasia. The hypercellular areas consisted of spindle to ovoid tumor cells proliferating in a collagenous stroma. In hypocellular areas, small vessels were scattered in an edematous, loosely arranged collagenous stroma. The clinical and histopathological features were consistent with the diagnosis of angiomyofibroblastoma of the vulva. We reviewed 215 reported cases of angiomyofibroblastoma from 1992 to 2021 in the literature and found that large growth and rapid enlargement simulating an aggressive angiomyxoma are not rare in angiomyofibroblastoma. Therefore, large vulvar tumors should be carefully managed by pre- and intraoperative examinations to avoid oversurgery.

    Download PDF (1209K)
Review
  • Koji Yoshino
    2022 Volume 132 Issue 6 Pages 1479-1487
    Published: May 20, 2022
    Released on J-STAGE: May 20, 2022
    JOURNAL RESTRICTED ACCESS

    Combined therapies with BRAF and MEK inhibitors are effective treatments for melanoma. However, these therapies are also associated with pyrexia incidence. In this review article, characteristics of pyrexia, such as incidence rate, timing, and recurrence, were reviewed on the basis of reports of clinical trials of BRAF and MEK inhibitors. This article emphasizes key points of pyrexia management in clinical practice, referring to previously reported guidelines, clinical reports, and other review articles. It is expected that the therapeutic outcome of melanoma will be improved further in clinical practice by maximizing the effects of BRAF and MEK inhibitors while managing adverse drug reactions, including pyrexia, appropriately in individual patients.

    Download PDF (695K)
Abstracts
feedback
Top